Eli Lilly launches weight-loss drug Mounjaro in India after drug regulator approval

Eli Lilly has launched its diabetes and weight-loss drug Mounjaro in India after receiving regulatory approval. With rising obesity and diabetes rates, India presents a significant market opportunity for the U.S.-based company. Mounjaro is already marketed in the UK and Europe for both conditions and under the name Zepbound for obesity in the U.S.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/okZyiDW
via IFTTT